In the last decade the work in our laboratory was focused on the molecular, cellular and circuit mechanisms of learning and memory. However, we have also studied animal models of genetic disorders affecting cognition. We are currently translating our findings into clinical interventions. For example,
Neurofibromatosis Type I (NF1) is an inherited disorder that affects cognitive function in 1/4500 people world-wide. Based on our studies of the molecular and cellular mechanisms disrupted by Nf1 mutations in mice, we developed treatments that reverse the learning deficits of the Nf1 mutant mice. Similarly, we have been able to develop treatments that reverse the learning deficits associated with
Tuberous Sclerosis (TSC) in mice. Now, we are involved in clinical trials to apply these findings to the treatment of learning disabilities in children with NF1 and TSC.